TrialCancer2015

Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

Nasser H Hanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.